Skip Navigation



Glycobiology Advance Access published online on May 25, 2005
Glycobiology, doi:10.1093/glycob/cwi083
This Article
Right arrow Advance Access manuscript (PDF) Freely available
Right arrow All Versions of this Article:
15/10/994    most recent
cwi083v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Pashov, A.
Right arrow Articles by Kieber-Emmons, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pashov, A.
Right arrow Articles by Kieber-Emmons, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oupjournals.org
Received March 22, 2005
Revised May 19, 2005
Accepted May 20, 2005

Article

Concanavalin A binding to HIV envelope protein is less sensitive to mutations in glycosylation sites than monoclonal antibody 2G12

Anastas Pashov 1, Stewart MacLeod 1, Rinku Saha 1, Marty Perry 2, Thomas C. VanCott 3, and Thomas Kieber-Emmons 1*

1 Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR, 72205
2 Department of Chemistry, Ouachita Baptist University, Arkadelphia, AR 71998
3 U.S. Military HIV Research Program, Rockville, MD 20850

* To whom correspondence should be addressed.
Thomas Kieber-Emmons, E-mail: tke{at}uams.edu


  Abstract

A number of mannose binding proteins inhibit divergent strains of human immunodeficiency virus type 1 (HIV-1) in in vitro models of viral infectivity, suggesting that targeting mannose residues in vaccine applications might offset the strain restriction typically observed in antibody responses to HIV vaccine preparations. Concanavalin A (ConA) behaves like neutralizing antibodies that do not interfere with CD4 binding of gp120 but rather with later events in virus entry. The design of mannose-based vaccines therefore depends on understanding the mode of binding of ConA to the envelope protein in comparison with other mannose binding proteins. Here we further compare the binding affinity and fine specificity of ConA for the envelope protein to that of the human antibody 2G12. The 2G12 antibody is of unusual structure recognizing a cluster of 12 linked mannose residues associated with Man9GlcNAc2. Molecular structure comparison for Man9GlcNAc2 recognition by ConA and 2G12 indicates that 2G12 has a more restricted specificity to high mannose glycans of gp120 which correlates with kinetic analysis assessed by surface plasmon resonance (SPR) and ConA inhibits 2G12 binding to gp120 but 2G12 does not inhibit ConA binding to gp120. ConA binding to Env proteins from four different HIV strains proves significantly less sensitive to mutations in the glycosylation sites than 2G12 binding to the proteins. Thus antibodies directed toward mannose epitopes reactive with ConA may prove to be more effective in the long run to thwart HIV infection and transmission.

Keywords: HIV/2G12/Concanavalin A/carbohydrates.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Virol.Home page
P. W.-P. Hong, S. Nguyen, S. Young, S. V. Su, and B. Lee
Identification of the Optimal DC-SIGN Binding Site on Human Immunodeficiency Virus Type 1 gp120
J. Virol., August 1, 2007; 81(15): 8325 - 8336.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.